So Nagai
About
So Nagai is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Epidemiology.
According to data from OpenAlex, So Nagai has authored 53 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Molecular Biology and 13 papers in Epidemiology. Recurrent topics in So Nagai's work include Diabetes Treatment and Management (19 papers), Diabetes Management and Research (12 papers) and Metabolism, Diabetes, and Cancer (10 papers). So Nagai is often cited by papers focused on Diabetes Treatment and Management (19 papers), Diabetes Management and Research (12 papers) and Metabolism, Diabetes, and Cancer (10 papers). So Nagai collaborates with scholars based in Japan and United States. So Nagai's co-authors include Hideaki Miyoshi, Chikara Shimizu, Takao Koike, Narihito Yoshioka, Tatsuya Atsumi, Akinobu Nakamura, Mitsumasa Kubo, Hiroshi Nomoto, Hiraku Kameda and Kyu Yong Cho and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.
In The Last Decade
So Nagai
51 papers receiving 702 citations
Peers
So Nagai
Shinichiro Koike United States
Ming Lu China
I‐Hsien Wu United States
Tenagne D. Challa Switzerland
Miroslava Šimáková Czechia
Atsushi Miura Japan
Kevin Vivot France
Valentina Sukonina Sweden
Pegah Poursharifi Canada
Yoshitake Cho United States
Citations per year, relative to So Nagai So Nagai (= 1×)
peers
Shinichiro Koike
Countries citing papers authored by So Nagai
Since
Specialization
Citations
This map shows the geographic impact of So Nagai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by So Nagai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites So Nagai more than expected).
Fields of papers citing papers by So Nagai
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by So Nagai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by So Nagai. The network helps show where So Nagai may publish in the future.
Co-authorship network of co-authors of So Nagai
This figure shows the co-authorship network connecting the top 25 collaborators of So Nagai. A scholar is included among the top collaborators of So Nagai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with So Nagai. So Nagai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nomoto, Hiroshi, Yuki Yamauchi, Kazuno Omori, et al.. (2024). Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease. Diabetes & Metabolism Journal. 48(3). 473–481.
2.
Takahashi, Akihiro, Hiroshi Nomoto, Hiroki Yokoyama, et al.. (2024). Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( MEGMI study). Diabetes Obesity and Metabolism. 27(3). 1466–1476.
3.
Nomoto, Hiroshi, Hiroki Yokoyama, Yuka Suzuki, et al.. (2023). Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 2 study). Diabetes Obesity and Metabolism. 26(3). 961–970.
4.
Takahashi, Yuka, Hiroshi Nomoto, Hiroki Yokoyama, et al.. (2023). Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study). Diabetes Obesity and Metabolism. 25(6). 1503–1511.
5.
Nomoto, Hiroshi, Yuka Takahashi, Hiroki Yokoyama, et al.. (2023). Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics. 15(8). 2163–2163.
6.
Miya, Aika, Akinobu Nakamura, Yuka Suzuki, et al.. (2023). Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study. Diabetes Obesity and Metabolism. 25(7). 1883–1889.
7.
Nakamura, Akinobu, Aika Miya, Yuka Suzuki, et al.. (2023). Positive association between proinsulin and fatty liver index in people with type 2 diabetes. Endocrine Journal. 71(2). 193–197.
8.
Yamaguchi, Tomomi, Shujiro Hayashi, So Nagai, et al.. (2023). Case report: further delineation of AEBP1-related Ehlers–Danlos Syndrome (classical-like EDS type 2) in an additional patient and comprehensive clinical and molecular review of the literature. Frontiers in Genetics. 14. 1102101–1102101.
9.
Nomoto, Hiroshi, Akinobu Nakamura, So Nagai, et al.. (2022). Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). BMJ Open. 12(5). e056885–e056885.
10.
Nomoto, Hiroshi, Akihiro Takahashi, Akinobu Nakamura, et al.. (2022). Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study). BMJ Open Diabetes Research & Care. 10(6). e002988–e002988.
11.
Kameda, Hiraku, Hiroshi Nomoto, Kyu Yong Cho, et al.. (2021). Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study. Journal of Diabetes Investigation. 12(11). 1978–1982.
12.
Cho, Kyu Yong, Hiroshi Nomoto, Akinobu Nakamura, et al.. (2021). Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Research and Clinical Practice. 180. 109069–109069.
13.
Nakamura, Akinobu, Aika Miya, Hiroshi Nomoto, et al.. (2021). The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study. Diabetology & Metabolic Syndrome. 13(1). 37–37.
14.
Miya, Aika, Akinobu Nakamura, Kyu Yong Cho, et al.. (2020). Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. Journal of Diabetes Investigation. 12(8). 1395–1399.
15.
Miya, Aika, Akinobu Nakamura, Hiroshi Nomoto, et al.. (2020). Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment. Journal of Diabetes Investigation. 12(5). 738–746.
16.
Nomoto, Hiroshi, Kyu Yong Cho, Kazuno Omori, et al.. (2020). Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. BMJ Open. 10(2). e034883–e034883.
17.
Nomoto, Hiroshi, Hiraku Kameda, Akinobu Nakamura, et al.. (2019). Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment. Frontiers in Endocrinology. 10. 131–131.
18.
Kono, Michihito, Tomoka Hasegawa, So Nagai, et al.. (2017). Palisaded neutrophilic and granulomatous dermatitis as a novel cause of hypercalcemia. Medicine. 96(21). e6968–e6968.
19.
Miyoshi, Hideaki, Sandra C. Souza, Mikiko Endo, et al.. (2009). Perilipin overexpression in mice protects against diet-induced obesity. Journal of Lipid Research. 51(5). 975–982.
20.
Nagai, So, Satoshi Taniguchi, Keiko Sakai, et al.. (2005). Long-term Effects of Octreotide Acetate on Glucose Metabolism among Acromegalic Patients. 48(5). 317–323.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shinichiro Koike Breakdown of academic impact, for papers by Ming Lu Breakdown of academic impact, for papers by I‐Hsien Wu Breakdown of academic impact, for papers by Tenagne D. Challa Breakdown of academic impact, for papers by Miroslava Šimáková Breakdown of academic impact, for papers by Atsushi Miura Breakdown of academic impact, for papers by Kevin Vivot Breakdown of academic impact, for papers by Valentina Sukonina Breakdown of academic impact, for papers by Pegah Poursharifi Breakdown of academic impact, for papers by Yoshitake Cho